Our Innovative Therapies
Translating regenerative medicine through breakthrough stem cell technologies
Revolutionary Stem Cell Therapies
At Chiron Therapeutics, we're developing cutting-edge autograft stem cell therapies powered by our proprietary Suspension-Induced Stem Cell Transition (SIST) technology. Our pipelines focus on translating patient cells into targeted therapies for cartilage regeneration and wound healing.
Pipeline 1 – Cartilage Regeneration
Using our unique SIST technology, we can reprogram human skin fibroblasts to generate cartilage-producing chondrocytes. This innovative approach offers a promising solution for treating joint injuries and degenerative conditions.
Our preclinical data demonstrates successful transformation of skin cells into functional chondrocytes, providing a more accessible and less invasive alternative to traditional methods.
Generating human cartilage-producing cells (chondrocytes) from human skin fibroblasts confirmed by Alcian blue staining (top) and Immunostaining (bottom).
Using the SIST platform, we can derive spheroids from dermal fibroblasts (top) and keratinocytes (bottom) that express mesenchymal stem cell (MSC)- and keratinocyte stem cell (KSC)-like properties that are favorable for wound healing in a clinical setting.
Pipeline 2 – Enhancing Wound Healing
Our second pipeline focuses on accelerating wound healing through innovative cell therapy. The SIST platform enables us to develop cells with properties ideal for treating complex wounds, including burn injuries and chronic ulcers.
These cells provide an alternate safe and efficiently scalable source for wound healing therapy that can overcome the challenges currently presented with the use of MSCs and KSCs.
Ready to Learn More?
Contact our team to discuss potential collaborations or investment opportunities in our groundbreaking stem cell therapies.